(LFMD) LifeMD - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 203m USD | Total Return: -66.7% in 12m
Avg Turnover: 4.11M
Qual. Beats: 0
Rev. Trend: 92.7%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -12.0 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
LifeMD, Inc. (LFMD) is a direct-to-patient telehealth provider operating in the United States. The company utilizes a vertical integration model, combining a proprietary technology platform with a network of affiliated medical providers and pharmacy services to manage patient care from diagnosis through prescription fulfillment.
The business operates through specialized brands including Rex MD for men’s health and ShapiroMD for hair loss treatments. LifeMD also maintains a general virtual primary care practice and has recently expanded into the metabolic health sector by offering GLP-1 weight management programs. The telehealth industry is characterized by high recurring revenue potential through subscription-based medication delivery and chronic care management.
While the company is classified under Health Care Equipment, its primary value driver is the digital health infrastructure that reduces traditional brick-and-mortar overhead. Investors may find it useful to examine ValueRay for a deeper look at the company’s valuation metrics.
- GLP-1 weight loss medication adoption drives significant subscription and revenue growth
- Strategic partnership with Medifast expands patient acquisition and distribution channels
- High marketing spend relative to revenue impacts path to sustained profitability
- Direct-to-patient telehealth regulatory changes affect prescription fulfillment and compliance costs
- Expansion of virtual primary care services increases long-term patient lifetime value
| Net Income: -16.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -3.51 > 1.0 |
| NWC/Revenue: 0.96% < 20% (prev -4.67%; Δ 5.63% < -1%) |
| CFO/TA 0.08 > 3% & CFO 5.66m > Net Income -16.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.3m) vs 12m ago 3.85% < -2% |
| Gross Margin: 85.89% > 18% (prev 0.88%; Δ 8.50k% > 0.5%) |
| Asset Turnover: 305.3% > 50% (prev 317.7%; Δ -12.41% > 0%) |
| Interest Coverage Ratio: -11.99 > 6 (EBITDA TTM -4.30m / Interest Expense TTM 1.17m) |
| A: 0.03 (Total Current Assets 51.7m - Total Current Liabilities 49.6m) / Total Assets 70.1m |
| B: -3.40 (Retained Earnings -238.3m / Total Assets 70.1m) |
| C: -0.20 (EBIT TTM -14.1m / Avg Total Assets 71.9m) |
| D: -4.32 (Book Value of Equity -237.8m / Total Liabilities 55.1m) |
| Altman-Z'' = -16.73 = D |
| DSRI: 1.03 (Receivables 9.86m/10.2m, Revenue 219.4m/233.9m) |
| GMI: 1.02 (GM 85.89% / 87.98%) |
| AQI: 0.87 (AQ_t 0.19 / AQ_t-1 0.22) |
| SGI: 0.94 (Revenue 219.4m / 233.9m) |
| TATA: -0.31 (NI -16.3m - CFO 5.66m) / TA 70.1m) |
| Beneish M = -3.42 (Cap -4..+1) = AA |
As of June 01, 2026, the stock is trading at USD 4.28 with a total of 974,007 shares traded.
Over the past week, the price has changed by +5.16%,
over one month by -8.55%,
over three months by +47.08% and
over the past year by -66.69%.
LifeMD has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy LFMD.
- StrongBuy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 9.9 | 130.8% |
P/E Forward = 12.7226
P/S = 1.0481
P/B = 13.5084
Revenue TTM = 219.4m USD
EBIT TTM = -14.1m USD
EBITDA TTM = -4.30m USD
Long Term Debt = 5.50m USD (estimated: total debt 6.17m - short term 671k)
Short Term Debt = 671k USD (from shortTermDebt, last quarter)
Debt = 6.17m USD (from shortLongTermDebtTotal, last quarter) (leases 6.17m already included)
Net Debt = -15.0m USD (calculated: Debt 6.17m - CCE 21.2m)
Enterprise Value = 187.6m USD (202.6m + Debt 6.17m - CCE 21.2m)
Interest Coverage Ratio = -11.99 (Ebit TTM -14.1m / Interest Expense TTM 1.17m)
EV/FCF = -73.65x (Enterprise Value 187.6m / FCF TTM -2.55m)
FCF Yield = -1.36% (FCF TTM -2.55m / Enterprise Value 187.6m)
FCF Margin = -1.16% (FCF TTM -2.55m / Revenue TTM 219.4m)
Net Margin = -7.41% (Net Income TTM -16.3m / Revenue TTM 219.4m)
Gross Margin = 85.89% ((Revenue TTM 219.4m - Cost of Revenue TTM 31.0m) / Revenue TTM)
Gross Margin QoQ = 84.85% (prev 81.82%)
Tobins Q-Ratio = 2.68 (Enterprise Value 187.6m / Total Assets 70.1m)
Interest Expense / Debt = 19.00% (Interest Expense 1.17m / Debt 6.17m)
Taxrate = 21.0% (US default 21%)
NOPAT = -11.1m (EBIT -14.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.73 (Total Current Assets 51.7m / Total Current Liabilities 71.2m)
Debt / Equity = 0.41 (Debt 6.17m / totalStockholderEquity, last quarter 15.0m)
Debt / EBITDA = 3.50 (negative EBITDA) (Net Debt -15.0m / EBITDA -4.30m)
Debt / FCF = 5.90 (negative FCF - burning cash) (Net Debt -15.0m / FCF TTM -2.55m)
Total Stockholder Equity = 9.43m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.61% (Net Income -16.3m / Total Assets 70.1m)
RoE = -6.56% (Net Income TTM -16.3m / Total Stockholder Equity 247.7m)
RoCE = -5.55% (EBIT -14.1m / Capital Employed (Equity 247.7m + L.T.Debt 5.50m))
RoIC = -52.36% (negative operating profit) (NOPAT -11.1m / Invested Capital 21.2m)
WACC = 14.01% (E(202.6m)/V(208.8m) * Re(13.98%) + D(6.17m)/V(208.8m) * Rd(19.00%) * (1-Tc(0.21)))
Discount Rate = 13.98% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.56 | Cagr: 11.96%
[DCF] Fair Price = unknown (Cash Flow -2.55m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.45 | # QB: 0
Revenue Correlation: 92.70 | Revenue CAGR: 27.33% | SUE: 0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=N/A | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.17 | Chg30d=+126.67% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=0.14 | Chg30d=-3.57% | Revisions=-20% | GrowthEPS=-7.8% | GrowthRev=+14.6%
EPS next Year (2027-12-31): EPS=0.52 | Chg30d=+15.73% | Revisions=-20% | GrowthEPS=+281.5% | GrowthRev=+18.2%
[Analyst] Revisions Ratio: -20%